OPCH earnings analysis
What we found in OPCH's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Option Care Health delivered 1.9% year-over-year Q2 revenue growth to $1.442 billion and increased operating income to $85.1 million, with GAAP diluted EPS of $0.35. However, gross margin fell 50 basis points to 18.5% and management continues to expect approximately $55 million of 2026 gross-profit pressure from CID dynamics. Cash conversion improved sharply, with six-month operating cash flow of $171.5 million, while the company retained $193.8 million of cash and $846.0 million of revolver capacity.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue grew and EPS improved sequentially
- Q2 revenue increased $26.3 million, or 1.9% year over year, to $1.4424 billion. Revenue also rose from $1.35 billion in Q1 2026, while reported diluted EPS improved from $0.29 sequentially to $0.35.
- Cost discipline supported operating leverage
- Operating income rose $2.4 million to $85.1 million, and operating margin expanded 10 basis points year over year to 5.9%, as SG&A declined $5.4 million, or 3.2%, to $164.7 million.
- Operating cash flow strengthened materially
- Six-month operating cash flow more than doubled to $171.5 million from $83.1 million, principally due to lower inventory levels and working-capital optimization initiatives.
- Liquidity supports operations and M&A
- Liquidity remained substantial, with $193.8 million of cash and cash equivalents and $846.0 million of net revolver availability at June 30, 2026.
- Material capital return capacity remains
- The company repurchased 7.35 million shares in May at an average price of $20.41, leaving $525.0 million authorized under the repurchase program.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Mix pressure reduced gross margin
- Gross profit fell $1.8 million year over year to $267.3 million despite a $26.3 million revenue increase, and gross margin contracted 50 basis points to 18.5% due to therapy-mix pressure.
- CID headwind remains substantial
- Management expects chronic inflammatory disease portfolio dynamics—including patient attrition and unfavorable therapy mix—to negatively affect 2026 gross profit by approximately $55 million.
- Buybacks reduced cash balance
- Cash and cash equivalents declined $38.9 million during the first six months of 2026 to $193.8 million, while financing outflows included $167.5 million of share repurchases.
- Debt carries meaningful interest obligation
- The company estimates interest payments of $295.5 million through the final maturities of its credit facilities, based on rates as of June 30, 2026.
- No new risk-factor disclosures
- No material changes to previously disclosed risk factors were reported in this 10-Q; Item 1A explicitly states there were no material changes from the 2025 Form 10-K.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.35
- Gross margin
- 18.5%
- Operating margin
- 5.9%
What they said about what is next.
The 10-Q MD&A does not provide quantitative revenue or EPS guidance. Management states it expects CID-related dynamics to reduce 2026 gross profit by approximately $55 million; quantitative full-year guidance was addressed separately in the earnings release.
The filing reads about the same as the one before it.
What came before.
- 10-Q · April 30, 2026
- Option Care Health reported Q1 2026 results with net revenue of $1.35 billion, slightly missing estimates by 0.3%, and an EPS of $0.40, exceeding expectations. The firm's revenue growth was driven by a high single-digit…
- 10-K · February 24, 2026
- Option Care Health describes itself as the largest independent home and alternate-site infusion provider with a national network (196 locations in 43 states) and a multidisciplinary clinical team of ~5,000. Revenue…
- 10-Q · April 29, 2025
- Option Care Health reported Q1 2025 net revenue of $1,332,972,000 (up $186,920,000 or 16.3% vs Q1 2024) with gross profit of $263,052,000 and net income of $46,742,000. Margins show slight compression (gross margin…
- 10-Q · July 31, 2024
- Option Care Health reported Q2 net revenue of $1,227,186,000 (three months ended June 30, 2024), up versus $1,069,072,000 in the prior-year quarter and modestly above the prior quarter (implied Q1 revenue…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing OPCH makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever